Novel and emerging innate immune therapeutic targets for pancreatic cancer

Expert Opin Ther Targets. 2018 Dec;22(12):977-981. doi: 10.1080/14728222.2018.1538361. Epub 2018 Oct 24.

Authors

Liang Wang¹, Imad Shureiqi², John R Stroehlein^{1

3}, Daoyan Wei¹

Affiliations

¹ a Department of Gastroenterology, Hepatology and Nutrition , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
² b Department of Gastrointestinal Medical Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
³ c Department of Patient Affairs , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

PMID: 30332892
DOI: 10.1080/14728222.2018.1538361

No abstract available

Keywords: Innate immune; STING; agonist; cyclic GMP-AMP synthase (cGAS); cyclic dinucleotides (CDNs); immune therapy; pancreatic cancer.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Carcinoma, Pancreatic Ductal / immunology
Carcinoma, Pancreatic Ductal / pathology
Carcinoma, Pancreatic Ductal / therapy*
Humans
Immunity, Innate
Immunotherapy / methods
Molecular Targeted Therapy*
Pancreatic Neoplasms / immunology
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / therapy*